The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 286-291

  Gail, Mitchell H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Benefits; Breast cancer prevention; Risks; SERMs

Indexed keywords

SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0035687052     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04034.x     Document Type: Conference Paper

References (6)

1. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
3. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
4. Validation studies for models projecting the risk of invasive and total breast cancer incidence
5. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention
6. Incidence rates of stroke in the eighties: The end of the decline in stroke?